# Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

> **NCT02535104** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tamir Biotechnology, Inc.** · enrollment: 70 (actual)

## Conditions studied

- Condylomata Acuminata
- Papillomavirus Infections
- Sexually Transmitted Diseases

## Interventions

- **DRUG:** Ranpirnase
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT02535104
- **Lead sponsor:** Tamir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535104, "Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02535104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*